Development of PARP inhibitors, which appear to work best in women with BRCA mutations, has faced setbacks recently. An article reviews the data, good and bad, about PARP inhibitors.
The article is here.
Ovarian Cancer National Alliance • 901 E Street NW, Suite 405 • Washington, DC 20004
(202) 331-1332 • toll-free: 1-866-399-6262 • fax: (202) 331-2292 • email@example.com
All content © Copyright 2013 by Ovarian Cancer National Alliance.
Subscribe to our RSS Feed or view our Sitemap
This site made possible by a grant from Novartis Oncology